These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 4184992)

  • 41. [Concept of endocrine ophthalmopathies].
    Heberting HJ; Schwarzmann E
    Z Gesamte Inn Med; 1974 Sep; 29(17):712-5. PubMed ID: 4141190
    [No Abstract]   [Full Text] [Related]  

  • 42. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
    Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
    J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Evolution of immunoglobulins IgA, IgM, IgG and LATS during treatment of hyperthyroidism with carmibazole and radioiodine].
    Mahaux JE; Delcourt R; Nagel M; Chamla-Soumenkoff J; Levin S
    Ann Endocrinol (Paris); 1970; 31(2):314-23. PubMed ID: 4192759
    [No Abstract]   [Full Text] [Related]  

  • 44. Long-acting thyroid stimulator and related factors.
    Kendall-Taylor P; Dirmikis SM; Munro DS
    Proc R Soc Med; 1975 Apr; 68(4):252-3. PubMed ID: 1242809
    [No Abstract]   [Full Text] [Related]  

  • 45. [Thyroid function and the state of the hypothalamus-hypophysis-thyroid in patients with diffuse toxic goiter after treatment].
    Aliakparova ASh
    Sov Med; 1973 Dec; 36(12):45-8. PubMed ID: 4130665
    [No Abstract]   [Full Text] [Related]  

  • 46. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
    Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
    J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
    [No Abstract]   [Full Text] [Related]  

  • 47. Correlation of long-acting thyroid stimulator with serum levels of tri-iodothyronine, thyroxine and thyrotropin in Graves' disease.
    Sawhney RC; Kannan V; Rastogi GK
    J Assoc Physicians India; 1975 Feb; 23(2):111-4. PubMed ID: 1242389
    [No Abstract]   [Full Text] [Related]  

  • 48. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
    Hardisty CA; Fowles A; Munro DS
    J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum long acting thyroid stimulator protector in pregnancy complicated by Graves' disease.
    Hardisty CA; Munro DS
    Br Med J (Clin Res Ed); 1983 Mar; 286(6369):934-5. PubMed ID: 6403139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The thyroid-stimulating antibody of Graves' disease: evidence for restricted heterogeneity.
    Zakarija M
    Horm Res; 1980; 13(1):1-15. PubMed ID: 6777285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Graves' IgG stimulation of continuously cultured rat thyroid cells: a sensitive and potentially useful clinical assay.
    Vitti P; Valente WA; Ambesi-Impiombato FS; Fenzi GF; Pinchera A; Kohn LD
    J Endocrinol Invest; 1982; 5(3):179-82. PubMed ID: 6286749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Graves' disease: thyroid function and immunologic activity.
    Gossage AA; Crawley JC; Copping S; Hinge D; Himsworth RL
    J Nucl Med; 1982 Nov; 23(11):973-7. PubMed ID: 6290623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Absence of thyroid-stimulating antibody and long acting thyroid stimulator in relatives of Graves' disease patients.
    Banovac K; Zakarija M; McKenzie JM; Witte A; Sekso M
    J Clin Endocrinol Metab; 1981 Sep; 53(3):651-3. PubMed ID: 6790561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Autoimmune aspect of exophthalmic goiter. Activation of cervical lymphoid structures and production of IgM and IgG immunoglobulins].
    Mahaux JE; Delcourt R; Chamla-Soumenkoff J; Nagel M
    Ann Endocrinol (Paris); 1969; 30(1):139-46. PubMed ID: 4180185
    [No Abstract]   [Full Text] [Related]  

  • 55. Relationships among immunoglobulin markers in Graves' disease.
    Ozawa Y; Maciel RM; Chopra IJ; Solomon DH; Beall GN
    J Clin Endocrinol Metab; 1979 Mar; 48(3):381-7. PubMed ID: 581874
    [No Abstract]   [Full Text] [Related]  

  • 56. Thyroid physiology and functional tests.
    Zellmann HE
    Major Probl Clin Surg; 1974; 15(0):55-70. PubMed ID: 4138680
    [No Abstract]   [Full Text] [Related]  

  • 57. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pathophysiology of the thyroid gland. Some newer aspects (author's transl)].
    Bürgi H
    Verh Dtsch Ges Pathol; 1977; 61():154-61. PubMed ID: 203137
    [No Abstract]   [Full Text] [Related]  

  • 59. 35-S-sulfate uptake by mouse harderian gland: effect of serum from patients with Graves' disease.
    Singh SP; McKenzie JM
    Metabolism; 1971 Apr; 20(4):422-7. PubMed ID: 5107990
    [No Abstract]   [Full Text] [Related]  

  • 60. Thyroid responsiveness in Gravesian ophthalmopathy.
    Mendelsohn LV; Mouton DE; Goldzieher JW
    Arch Intern Med; 1972 Jul; 130(1):119-20. PubMed ID: 5067864
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.